<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864432</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL020</org_study_id>
    <nct_id>NCT03864432</nct_id>
  </id_info>
  <brief_title>An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)</brief_title>
  <official_title>An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetic properties, safety and tolerability of single/multiple oral
      administration of Gemigliptin and Food effect in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">October 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Gemigliptin</measure>
    <time_frame>0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 16h, 24h, 36h, 48h and 72h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Gemigliptin</measure>
    <time_frame>0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 12h, 16h, 24h, 36h, 48h and 72h</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>25mg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg Multiple dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 25mg</intervention_name>
    <description>Gemigliptin 50mg 1/2T</description>
    <arm_group_label>25mg SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 50mg</intervention_name>
    <description>Gemigliptin 50mg 1T</description>
    <arm_group_label>50mg SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 100mg</intervention_name>
    <description>Gemigliptin 50mg 2T</description>
    <arm_group_label>100mg SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemiglptin 50mg multiple dose</intervention_name>
    <description>Gemigliptin 50mg 1T * 10days</description>
    <arm_group_label>50mg Multiple dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects (aged 19~45 years at the time of screening)

          -  Subjects weighing between 50kg (inclusive) and 90kg (exclusive), and having a body
             mass index (BMI) of 17.1～25.8 (inclusive of limits).

          -  Subjects with a fasting plasma glucose (FPG) of 70～110mg/dL (inclusive of limits) at
             the time of screening

          -  Subjects who are willing to participate in the entire study cycle and comply with the
             study protocol (including contraception). Subjects who can sign the written Informed
             Consent Form after being informed of the study procedures.

        Exclusion Criteria:

          -  Those with a history of allergies including drug allergies (aspirin, antibiotics,
             etc.), or other clinically significant allergies.

          -  Those with diseases of the liver (including carriers of hepatitis virus), kidney,
             respiratory system, endocrine system, nervous system or immune system. Those with a
             medical history of hematology/oncology, psychiatry or cardiovascular diseases.

          -  Those with a medical history of gastrointestinal diseases (ulcers, Crohn's disease,
             etc.) or surgery (excluding simple appendectomy or hernia repair), and these
             situations can affect the absorption of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-Mei Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Xuhui District Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xuhui Central hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

